Cart
sales@molnova.com
CDK12-IN-5
CAS No. 2651200-35-8
CDK12-IN-5( —— )
Catalog No. M35197 CAS No. 2651200-35-8
CDK12-IN-5 is a potent CDK12 inhibitor with potential anticancer and antitumor activity, and can be used orally in the study of breast and ovarian cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 440 | In Stock |
|
| 5MG | 398 | In Stock |
|
| 10MG | 645 | In Stock |
|
| 25MG | 1321 | In Stock |
|
| 50MG | 2037 | In Stock |
|
| 100MG | 2762 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK12-IN-5
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK12-IN-5 is a potent CDK12 inhibitor with potential anticancer and antitumor activity, and can be used orally in the study of breast and ovarian cancer.
-
DescriptionCDK12-IN-5, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC50 of 23.9 nM at high ATP (2 mM). CDK12-IN-5 has no effect on CDK2/Cyclin E (IC50=173 μM) and CDK9/Cyclin T1 (IC50=127 μM) at high ATP (2 mM) (WO2021116178A1).
-
In VitroCDK12-IN-5 (Example 426) inhibits BRCA1 MRNA expression in MDA-MB-231 cells (IC50=3.23 nM) and has no effect on CAL-120 cells. CDK12-IN-5 has antproliferative activity in MDA-MB-231 cells (IC50=4.19 nM) and CAL-120 cells (IC50=3.57 nM). CDK12-IN-5 has a inhibition IC50 CDK12 high ATP to Degradation DC50 CDK12 ratio of 32.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2651200-35-8
-
Formula Weight454.36
-
Molecular FormulaC18H15F5N8O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (275.11 mM; Ultrasonic )
-
SMILESFC=1C=CC=2N=C(NC2C1F)CNC3=NC(=NC4=C(C=NN34)C(F)(F)F)N5CCOCC5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kai Thede, et al. Pyrazolotriazines. WO2021116178A1.
molnova catalog
related products
-
CDK9-IN-7
CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).
-
A-674563 HCl (552325...
A-674563 is an orally available, ATP-competitive, and reversible inhibitor of Akt (Ki: 11 nM for Akt1) .
-
CDK5-IN-3
CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA and can be used in the study of cancer.
